KDR and ovarian carcinoma: For example, several clinical trials are currently evaluating combined VEGF/VEGFR and PD-1/PD-L1 inhibitors for various cancer types including renal cell carcinoma, recurrent glioblastoma, ovarian cancer and colorectal cancer (NCT03024437, NCT02659384, NCT02873962, NCT02017717).